Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 CongressGlobeNewsWire · Sep 4, 2026
Rein Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewsWire · Sep 3, 2026
Here's Why You Should Add RNTX Stock to Your Portfolio NowZacks Investment Research · Sep 3, 2026
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewsWire · Aug 20, 2026
Brokerages Set Rein Therapeutics Inc. (NASDAQ:RNTX) PT at $6.00Defense World · Aug 17, 2026
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.17 | -$0.10 | Beat |
| May 15, 2026 | -$0.49 | -$0.19 | Beat |
| Mar 26, 2026 | -$1.09 | -$1.09 | Beat |
| Nov 14, 2025 | -$0.24 | -$0.21 | Beat |
| Aug 14, 2025 | -$0.22 | -$0.28 | Miss |
| Apr 7, 2025 | -$0.14 | -$0.26 | Miss |